From tracking InsurTech funding rounds across eight consecutive quarters, the acceleration in AI deal sizes from $11 million averages in early 2025 to $25.79 million in Q1 2026 marks a structural shift in where venture capital sees defensible insurance value. On May 7, 2026, Gallagher Re published its Q1 2026 Global InsurTech Report documenting what may be the most concentrated funding environment in the sector's history: AI-focused startups captured a record 95.2% of all InsurTech venture capital, pulling $1.55 billion across 68 deals. Every single top-ten deal in the quarter involved an AI company. This is not a gradual trend; it represents a near-total reallocation of InsurTech capital toward artificial intelligence in a single quarter.

Most trade press coverage reports the 95.2% headline and moves on. This article goes deeper into three dynamics the headline obscures. First, the Life/Health versus P&C funding split reversed sharply, with L&H nearly doubling to $719 million while P&C fell 31% to $907 million, signaling sector rotation toward historically underserved lines. Second, early-stage deal sizes surged 278.8% year-over-year to $14.06 million, the highest since Q3 2022, concentrating risk in fewer but larger bets. Third, a $444.84 million cluster of AI liability and cyber insurance deals signals rapid formation of an entirely new product category. Together, these shifts reshape carrier procurement strategy, build-versus-buy calculations, and actuarial approaches to pricing novel AI-driven exposures.

The Headline Numbers: $1.63 Billion and What Changed

Q1 2026 InsurTech funding reached $1.63 billion, down marginally from $1.67 billion in Q4 2025. That sequential flatness obscures a more significant signal: the two quarters combined mark the strongest consecutive InsurTech funding activity since Q3 2022. Andrew Johnston, Gallagher Re's Global Head of InsurTech, characterized the back-to-back performance as "bucking the now three-year trend of quarterly funding of around USD 1 billion."

Metric Q1 2026 Q4 2025 Change
Total InsurTech funding $1.63B $1.67B -2.4%
AI-focused firm share 95.2% 77.9% +17.3 pp
AI-focused firm funding $1.55B n/a n/a
AI deal count 68 n/a n/a
Average AI deal size $25.79M $22.14M +16.5%
Top 10 deals to AI firms 10 of 10 n/a Record

For historical context, InsurTech funding peaked at $15.8 billion annually in 2021 before collapsing 55% to $7.1 billion in 2022. It continued sliding through 2023 ($4.5 billion) and 2024 ($4.25 billion) before the first annual increase since 2021 arrived in 2025 at $5.08 billion, a 19.5% rebound. Cumulative InsurTech investment through mid-2025 reached approximately $60 billion globally, with roughly $15 billion flowing to AI-focused firms. The Q1 2026 AI concentration figure suggests that ratio is accelerating sharply.

The jump from 77.9% AI share in Q4 2025 to 95.2% in Q1 2026 crossed a threshold that transforms how the InsurTech label functions. When 19 out of every 20 venture dollars flow to AI companies, "InsurTech" and "insurance AI" become operationally synonymous for capital allocation purposes. Johnston stated this directly: "AI and InsurTech are now almost synonymous."

Where the Capital Is Concentrating: The Top Deals

The three largest Q1 2026 deals collectively raised $335 million and illustrate three distinct AI insurance thesis categories: AI-native underwriting platforms, AI liability coverage for model risk, and AI-driven claims processing infrastructure.

Corgi: $160 Million Series B, AI-Native Carrier

Corgi closed a $160 million Series B led by TCV at a $1.3 billion valuation, reaching unicorn status just four months after its Series A. The Y Combinator Summer 2024 graduate holds a carrier license (approved July 2025) and writes policies on its own paper across D&O, E&O, cyber, commercial general liability, and a dedicated AI liability product covering biased algorithms, hallucination-driven losses, training data misuse, adversarial attacks, and autonomous system failures. Total funding has reached $268 million. COO Emily Yuan, a former OpenAI product manager, described the company's thesis: "Insurance is one of the largest industries in the world, but it's still built on infrastructure from centuries ago." The speed-to-quote metric of under ten minutes versus the two-to-four-week traditional cycle represents a structural change in commercial insurance distribution, not merely an operational improvement. Our deep analysis of Corgi's valuation and actuarial pricing challenge examines what it means to price a liability line with zero credible loss history.

Reserv: $125 Million Series C, AI-Native Claims

Reserv raised $125 million in a Series C led by KKR, with participation from Bain Capital Ventures and Flourish Ventures. The company has reached $100 million in annual recurring revenue and employs more than 500 claims adjusters serving nearly 200 insurers, MGAs, brokers, and corporate captives. Its current capacity handles approximately 500,000 complex claims annually, with a four-year target of 30 million claims. CEO CJ Przybyl, who co-founded Reserv in 2022 with Martha Dreiling, built the Reserv Glance platform to deliver fully explainable AI for claims triage and adjudication. Carriers consolidate historical and live claims into a single database, with legacy system phase-outs achievable "within weeks" according to the company. KKR's lead position is notable because it signals private equity conviction that AI claims processing infrastructure can deliver returns at the scale KKR's fund economics require.

Counterpart: $50 Million Series C, SME Cyber and AI Risk

Counterpart raised $50 million in a Series C led by Valor Equity Partners, bringing total funding to $106 million. The company has processed more than 250,000 applications, written over 35,000 policies through 2,800 brokers backed by four A-rated carriers, and grew premium nearly 175% in 2025. Its claims resolution operates more than two times faster than sector benchmarks, with outcomes more than 10% better than industry standards. CEO Tanner Hackett framed the market opportunity around small business exposure: "We are witnessing a generation of small business owners walking into the most litigious environment in American history without protection." The Series C will fund new specialty products, industry-specific programs, and capitalization of Counterpart Insurance Company. Counterpart's positioning at the intersection of cyber and AI liability for the SME segment addresses a coverage gap that traditional carriers have been slow to fill.

Life/Health vs. P&C: The Sector Rotation

One of the most significant and underreported shifts in the Q1 2026 data is the sector rebalancing between Life/Health and P&C InsurTech funding.

Segment Q1 2026 Funding Quarterly Trend
Life & Health $718.99M Nearly doubled QoQ
Property & Casualty $907.14M -31% QoQ

Throughout 2025, P&C dominated InsurTech funding at $3.49 billion (up 34.9% year-over-year) while Life/Health dipped 4.6% to $1.59 billion. The Q1 2026 data reverses that trend sharply. Life/Health funding nearly doubled quarter over quarter while P&C declined 31%.

Several forces explain the rotation. First, the GLP-1 disruption is creating demand for AI-driven underwriting and claims analytics in health insurance. Carriers and stop-loss writers need predictive models that can distinguish between GLP-1 utilization patterns that reduce long-term morbidity and those that create short-term pharmacy spend spikes without corresponding medical cost offsets. Second, the Medicare Advantage rate methodology changes, including the CMS 2027 rate reversal and the unlinked chart review ban, are forcing health plan actuaries to rebuild pricing infrastructure in ways that create natural entry points for AI vendors. Third, the LDTI reporting requirements that went live for non-public life insurers in 2025 created operational complexity that AI-driven analytics platforms can address more efficiently than manual actuarial workflows.

For carriers evaluating build-versus-buy decisions, the L&H funding surge means the vendor landscape is expanding rapidly in a segment that historically had fewer InsurTech options than P&C. Chief actuaries at life and health carriers who evaluated and dismissed the InsurTech vendor pool in 2024 should resurvey the market, because the companies entering in 2026 have meaningfully larger capital bases and more mature products than those available 18 months ago.

Early-Stage Deal Sizes Surge 278.8%: Fewer Bets, Bigger Checks

The early-stage investment data reveals a market structure that is becoming simultaneously more concentrated and more confident:

Early-Stage Metric Q1 2026 Year-Over-Year Change
Total early-stage funding $548.50M +36.1% QoQ
Average early-stage deal size $14.06M +278.8% YoY
Highest level since Q3 2022

CB Insights corroborates the concentration pattern from a different angle. Its Q1 2026 State of InsurTech report found the median deal size climbed to $10.0 million, nearly double the $5.3 million peak recorded during the 2021 funding surge. But the deal count fell to just 81 in Q1 2026, the lowest since Q2 2016 when only 67 deals closed. The market is placing fewer bets at dramatically higher conviction levels.

The investor pool itself is thinning. CB Insights found the number of investors making four or more equity investments fell to a nine-year low in 2025, and the global active investor count dropped to its lowest level since Q3 2020. Insurance corporate venture capital (CVC) participation reached a near-decade low: only four insurance CVCs invested in Q1 2026 (American Family Ventures, Intact Ventures, Optum Ventures, and Sancor Seguros Ventures), matching the count last seen in Q4 2017.

This matters for carriers because the CVC retreat creates an information gap. CVC-backed InsurTechs earned an average Mosaic Score of 545 out of 1,000, which is 29% higher than the 422 average for non-CVC-backed companies, according to CB Insights. If carriers are not investing alongside InsurTechs, they lose the governance visibility, strategic alignment, and early access that CVC participation provides. The result is that carriers are increasingly encountering AI InsurTech vendors as customers rather than as investors, which shifts negotiating dynamics and reduces the carrier's ability to influence product roadmaps.

The $444.84 Million AI Liability and Cyber Convergence

AI liability and cyber insurance firms raised $444.84 million in Q1 2026 alone. Gallagher Re frames this as rapid formation of a "digital risks" product category that blurs the boundaries between standalone cyber, professional indemnity, and the emerging AI liability line.

Cumulative digital and cyber risk InsurTech funding since 2012 has reached $5.77 billion across 263 deals. The Q1 2026 quarter represented 7.7% of that cumulative total in a single three-month period, illustrating the acceleration.

Freddie Scarratt, Gallagher Re's Global Deputy Head of InsurTech, connected AI liability to the cyber insurance growth trajectory: "The emerging landscape of third-party AI liability insurance is a fast-growing necessity, poised to mirror the explosive growth we've witnessed in the cyber reinsurance market." He went further on the silent risk dimension: "The accumulation of silent AI risk represents a fundamental threat to underwriting discipline. It creates a scenario where insurers are providing 'accidental' capacity for complex, high-stakes events they have neither modelled nor priced."

That silent risk warning carries particular weight for reserving actuaries. If AI model failures trigger losses under existing general liability, professional liability, or technology E&O policies that were not priced with AI exposure in mind, the development on those lines will diverge from historical patterns in ways that traditional actuarial methods will struggle to detect until the claims mature. The Verisk ISO Gen AI exclusion endorsement, which we analyzed in detail, is the market's attempt to separate this silent exposure, but adoption remains uneven across carriers and lines.

Standalone AI liability insurers entering the market now include Munich Re (insureAI performance guarantees), Corgi (carrier-licensed, full AI liability form), Armilla (Lloyd's syndicate-backed), Mayflower Specialty, and Embroker, offering limits from $2 million to $50 million. The emergence of multiple competitors writing affirmative AI coverage suggests the market is moving past the proof-of-concept stage toward a contested pricing environment, even though credible loss data remains essentially nonexistent.

What the CB Insights Data Reveals About Market Structure

Beyond the funding totals, the CB Insights Q1 2026 report exposes structural dynamics that have implications for InsurTech vendor longevity:

Re-raise timelines are extending. Eighty-two percent of InsurTechs that raised in Q1 2026 will not be ready to raise again for at least six months, which is 17 percentage points longer than the broader venture market. Compared to AI, digital health, and fintech, InsurTech has the longest wait before the next funding round. This suggests that InsurTech AI companies need to demonstrate faster paths to revenue than their counterparts in adjacent sectors to sustain investor interest.

Non-insurance CVCs remain more active. While insurance CVC participation dropped to four, ten non-insurance CVCs remained active in Q1 2026. This dynamic means that InsurTech AI companies are increasingly funded by investors without deep insurance domain expertise, which can create misalignment between product development priorities and carrier procurement requirements. A general-purpose AI investor may push for horizontal platform expansion while a carrier customer needs deep vertical integration with legacy policy administration systems.

Deal count compression signals consolidation ahead. The 81 deals in Q1 2026 represent the lowest quarterly count in a decade. When fewer companies receive funding but each receives substantially more capital, the competitive landscape is narrowing. Carrier Management compared the current AI vendor proliferation to early-2000s internet companies, with the expectation that most vendors will not survive. Kurt Diederich, CEO of Finys, warned that "carriers that approach AI as a static investment risk are accumulating technical and operational constraints that limit their abilities to adapt as the market consolidates and evolves."

Carrier Build-vs-Buy Implications

The funding concentration reshapes the build-versus-buy calculation for carriers in several ways that our analysis of the insurance AI J-curve anticipated.

Vendor capitalization has reached carrier-grade scale. When Reserv has $100 million in ARR and Corgi has $268 million in total funding, these are not fragile startups that might disappear mid-implementation. They have the capital to support multi-year carrier integration projects. The early-stage InsurTech risk that made carrier procurement teams cautious in 2022 through 2024 is structurally different from the 2026 landscape, where the average AI deal size of $25.79 million provides meaningful operational runway.

AI compresses development timelines enough to reopen build decisions. Analysis from hyperexponential and Carrier Management indicates that rating model development has compressed from three months to between 30 minutes and one hour using AI-assisted tools. That compression reopens build decisions that carriers previously resolved in favor of buying because the development burden was too high. The conversation shifts from buying to avoid building, to buying platforms that accelerate internal building.

The vendor landscape is narrowing while capability is deepening. Fewer InsurTech deals at higher dollar amounts means fewer viable vendor options within each functional category. Carriers that delay procurement decisions risk facing a more consolidated vendor market with less competitive pricing leverage. At the same time, the vendors that do survive will have deeper products and larger customer bases, which can improve implementation outcomes. Insurance enterprises operate on ten-year horizons; the vendors best positioned for carrier relationships are those with vertical domain expertise and capital to match that timeframe.

Our coverage of carriers building AI expense savings into forward guidance documented AIG's sub-30% expense ratio target, Chubb's 1.5 combined ratio point automation savings, and Travelers' $1.5 billion infrastructure allocation. Those forward-looking expense projections depend on the InsurTech vendor ecosystem delivering on its promises. The $1.55 billion in AI-focused InsurTech funding in Q1 2026 provides the capital base to fulfill those commitments, but execution risk remains.

The Contrarian Case: Concentration Risk and ROI Questions

The 95.2% AI concentration figure invites a contrarian question: does this level of capital commitment outpace the insurance industry's demonstrated ability to extract value from AI investments?

The evidence for caution is substantive. A Yale Insights analysis citing an MIT study found that 95% of 52 organizations achieved zero ROI despite $30 to $40 billion in generative AI spending across more than 300 initiatives. Nearly two-thirds of U.S. venture deal value flowed to AI and machine learning startups in the first half of 2025, up from 23% in 2023. That velocity of capital reallocation carries concentration risk that extends beyond individual company performance.

Goldman Sachs CEO David Solomon acknowledged that "a lot of capital that was deployed doesn't deliver returns." Sam Altman of OpenAI stated directly that "people will overinvest and lose money." Even Dario Amodei of Anthropic estimated a 25% probability that AI development goes "really, really badly." These are not external skeptics; these are the leaders of the companies absorbing the capital.

Bank of America quantified one dimension of the insurance-specific risk: $15 billion in insurance industry commissions identified as "low complexity" facing AI disintermediation, with organic revenue growth at risk of slipping from 3-7% to 1-5% and 10-20% of current business facing disintermediation. Insurance broker stocks initially fell 9% in February 2026 following AI chatbot launches by Insurify and Tuio, then recovered 7% over three weeks, a volatility pattern characteristic of markets pricing a real but uncertain structural shift.

Risk & Insurance highlighted the "return on investment paradox" in insurance AI: efficiency gains free up resources and time for employees but fail to provide clear direction on how to utilize those newly available resources. The industry invested over $1 trillion in AI infrastructure in 2025 across big tech, yet valuations outpaced revenue generation. For InsurTech specifically, our analysis of insurance AI ROI pilots showed that measurable performance gains remain concentrated in narrow use cases rather than the broad operational transformation that AI vendor marketing materials promise.

The bull case and the bear case are not mutually exclusive. AI is almost certainly transforming insurance operations. And a significant fraction of the $1.55 billion deployed in Q1 2026 will generate negative returns. The actuarial question is not whether AI works in insurance but which specific applications, at which carriers, will generate positive marginal returns net of implementation costs, organizational disruption, and the opportunity cost of alternative investments.

Why This Matters for Actuaries

The Gallagher Re Q1 2026 data has direct implications across actuarial practice areas:

Pricing actuaries working on technology E&O, cyber, and commercial general liability need to understand how the $444.84 million in AI liability and cyber funding is creating a new competitive dynamic. New entrants like Corgi and Counterpart are writing at speed and price points that established carriers cannot match with legacy underwriting workflows. The pricing benchmarks being set by AI-native carriers may not be actuarially defensible given zero credible loss history, but they will set market expectations that influence renewal negotiations across the portfolio.

Reserving actuaries at carriers with InsurTech vendor relationships should monitor the deal count compression and re-raise timeline data. If the 82% re-raise delay rate signals financial stress at some InsurTech vendors, carriers using those vendors face implementation continuity risk. Continuity risk should factor into operational reserve considerations, particularly for carriers that have committed to specific AI-driven claims or underwriting workflows that depend on a single vendor's technology.

Enterprise risk actuaries evaluating AI vendor concentration should note the parallel between the 95.2% AI funding share and the 90% OpenAI concentration we documented in carrier AI stacks. If a small number of AI InsurTech vendors capture the majority of carrier procurement dollars (mirroring the venture capital concentration), the insurance industry adds vendor-level systemic risk. A single vendor failure or model degradation event could propagate across multiple carriers simultaneously.

Chief actuaries involved in strategic planning should use the Life/Health funding surge as a signal to reassess the InsurTech vendor landscape in their segment. The near-doubling of L&H InsurTech funding means new vendors are entering with capabilities that did not exist 12 months ago. For life and health carriers that have relied on internal actuarial teams for analytics and modeling, the build-versus-buy calculus has shifted.

Patterns we have seen across multiple InsurTech funding cycles suggest that capital concentration of this magnitude precedes a period of rapid vendor consolidation, followed by a stabilization phase where surviving vendors have sufficient scale to become durable carrier partners. The actuarial question is timing: carriers that commit too early risk vendor failure, while those that wait too long face a consolidated market with fewer choices and higher switching costs.

Further Reading

Sources